PharmaCyte Biotech, Inc. carries no debt; cash flow comfortably covers obligations.

PharmaCyte Biotech, Inc.'s free cash flow has decreased 38.43% from $-2.15M last year to $-2.98M, signaling decreasing performance

PharmaCyte Biotech, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

PharmaCyte Biotech, Inc. has insufficient data to evaluate this check.

PharmaCyte Biotech, Inc. has a net cash position, so leverage is healthy.

PharmaCyte Biotech, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

PharmaCyte Biotech, Inc. has insufficient data to evaluate this check.

PharmaCyte Biotech, Inc.'s short-term assets of $37.42M exceed its short-term liabilities of $826.42K

PharmaCyte Biotech, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

PharmaCyte Biotech, Inc.'s return on equity of -50.84%, is lower than 15.00%, indicating bad performance

PharmaCyte Biotech, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

PharmaCyte Biotech, Inc. had positive net income in only 2 out of 5 years, indicating unstable earnings

PharmaCyte Biotech, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

PharmaCyte Biotech, Inc. has negative free cash flow, indicating cash burn

PharmaCyte Biotech, Inc.'s yearly earnings has decreased 163.36% since last year from $30.66M to $-19.42M, signaling decreasing performance

PharmaCyte Biotech, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -11.55% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

PharmaCyte Biotech, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

PharmaCyte Biotech, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

PharmaCyte Biotech, Inc. had positive ROE in only 2 out of 5 years, indicating inconsistent returns on equity

PharmaCyte Biotech, Inc. has insufficient data to evaluate this check.

PharmaCyte Biotech, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

PharmaCyte Biotech, Inc. is undervalued relative to its fair value price of 33.81 based on EBITDA multiple model

PharmaCyte Biotech, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

PharmaCyte Biotech, Inc. has insufficient data to evaluate this check.

PharmaCyte Biotech, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

PharmaCyte Biotech, Inc. has a price-to-book ratio of 0.17x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

PharmaCyte Biotech, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue